CLINICAL ROLE -
EP. 1: Relapsed/Refractory Multiple Myeloma: Disease Overview
A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.
EP. 2: Treatment Pathways for Relapsed/Refractory Myeloma
Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.
EP. 3: IV Versus Subcutaneous Daratumumab
Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.
EP. 4: Backbone Regimens for Relapsed/Refractory Myeloma
Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.
EP. 5: mAb-based Therapies for Relapsed/Refractory Myeloma
Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.
EP. 6: Novel Agents for Relapsed/Refractory Myeloma
Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.
EP. 7: Belantamab Mafodotin for RRMM
Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.
EP. 8: RRMM: Adopting Anti-BCMA Therapy into Practice
Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.
EP. 9: RRMM: Educating Pharmacists on Anti-BCMA Therapy
The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.
EP. 10: Clinical Trials of Interest in RRMM
Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.
EP. 11: Optimizing Therapy for Patients With RRMM
Advice for clinical pharmacists who help manage patients with relapsed/refractory multiple myeloma in the current era of novel therapies and recommendations to improve upon current practice patterns.
2 Clarke Drive Cranbury, NJ 08512